22:27 , Jun 14, 2019 |  BC Extra  |  Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

Flatiron Health Inc. hired Michael Vasconcelles as CMO. Vasconcelles, who was CMO of Unum Therapeutics Inc. (NASDAQ:UMRX), succeeds Amy Abernethy, who left to join FDA as principal deputy commissioner early this year. The Roche (SIX:ROG;...
23:12 , May 21, 2019 |  BC Extra  |  Clinical News

BioCryst makes case for oral HAE therapy even as Phase III data disappoint investors

Despite reporting Phase III efficacy data for its oral hereditary angioedema therapy that fell short of marketed injectable therapies to prevent HAE attacks, BioCryst believes the demand for an oral option will enable BCX7353 to...
12:00 , May 20, 2019 |  BioCentury  |  Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
19:33 , May 17, 2019 |  BC Extra  |  Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval  FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support,...
23:54 , May 8, 2019 |  BC Extra  |  Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

Takeda off-loads Xiidra, TachoSil  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will sell Xiidra lifitegrast to Novartis AG (NYSE:NVS; SIX:NOVN) for $3.4 billion up front, plus $1.9 billion in milestones. Takeda said divesting the dry eye...
21:25 , May 1, 2019 |  BC Extra  |  Company News

Management tracks: Gilead, bluebird, Apollomics

Gilead Sciences Inc. (NASDAQ:GILD) said Robin Washington will retire as EVP and CFO, effective March 1, 2020. Washington, who joined Gilead in 2008, will continue in her role while the company identifies a successor. Gene...
14:00 , Apr 11, 2019 |  BC Extra  |  Financial News

TPG, Vida back Asklepios in $235M round

TPG Capital and Vida Ventures have again teamed up to invest in a biotech's megaround, pouring a combined $225 million into gene therapy company Asklepios in exchange for a undisclosed minority stake. The company's founders...
20:38 , Apr 9, 2019 |  BC Extra  |  Company News

Management tracks: Cyclerion, Alkermes, Alder

A week after completing its spinout from Ironwood, Cyclerion has hired Andreas Busch as chief innovation officer. Busch was EVP, head of R&D and CSO at Shire plc and previously served as EVP, head of...
23:40 , Apr 8, 2019 |  BC Extra  |  Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) hired Frederick Hausheer as CMO. He was CEO of Alpha Omega Oncology Services (San Antonio, Texas) and an associate partner at Alacrita Consulting (Waltham, Mass.). Antibody company Kymab Group...
18:37 , Apr 4, 2019 |  BC Extra  |  Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

FDA Commissioner Scott Gottlieb will return to the American Enterprise Institute as a resident fellow after he leaves the agency. His last day at FDA is Friday. Gottlieb expects to work part-time at AEI, where...